Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 22, 2026 | May 26, 2026 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Medical Officer | September 28, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date May 22, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 45,871 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 45,871 · Balance 45,871 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
NEUROCRINE BIOSCIENCES INC
Report date September 28, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,331 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 51,331 F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $102.90 · Expires 2030-02-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.63 · Expires 2031-02-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2032-01-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $136.69 · Expires 2034-12-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $124.12 · Expires 2036-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance Not disclosed F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award. |
Filing footnotes · ownership attribution and instrument terms
F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.
F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.
F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.
F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.
F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 76,275 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 40,625 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 26, 2026 23:02 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 45,871 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-26-000082 · form4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,871 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 74,872 | Not disclosed Strike: $5.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · derivative · entry 6 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4 · derivative.exercise_date: Each Option vested in full in connection with consummation of the Merger. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 42,467 | Not disclosed Strike: $10.27 | Not disclosed |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · derivative · entry 5 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 30,474 | Not disclosed Strike: $12.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · derivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 45,423 | Not disclosed Strike: $8.55 | Not disclosed |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerStock Options (right to buy) · Derivative | 40,625 | Not disclosed Strike: $10.71 | Not disclosed |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,625 shares Expires 2031-06-10 F2 · kind: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F2 · price: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 20:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Disposition to issuerCommon Stock | 76,275 | $14.50 | $1,105,987.50 |
DisclosureSEC source: 0001193125-26-182275 · ownership.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:53 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 74,872 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000950170-25-083215 · ownership.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,872 Underlying: Common Stock · 74,872 shares Expires 2035-06-05 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:53 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 20,414 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083215 · ownership.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,275 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 500 | $115.04 | $57,521.25 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 6 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,640 F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F6 · balance_after: 34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,372 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · derivative · entry 11 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 1,372 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F12 · derivative.exercise_date: This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award. F12 · derivative.expiration_date: This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · derivative · entry 10 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,363 Underlying: Common Stock · 1,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award. F11 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,113 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · derivative · entry 9 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,227 Underlying: Common Stock · 2,113 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F10 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award. F10 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,372 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 5 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 604 | $116.74 | $70,510.42 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,768 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,120 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,114 | $116.90 | $130,232.06 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,252 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,113 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 8,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · derivative · entry 8 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,108 Underlying: Common Stock · 8,108 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 43,261 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000069 · wk-form4_1739576520.xml · derivative · entry 7 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,261 Underlying: Common Stock · 43,261 shares Expires 2035-02-12 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $118.22 | $115,852.66 |
DisclosureSEC source: 0000914475-25-000051 · wk-form4_1739404337.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,253 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.07 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 32,068 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000051 · wk-form4_1739404337.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000051 · wk-form4_1739404337.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000029 · wk-form4_1738709691.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,769 Underlying: Common Stock · 2,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,768 shares on January 31, 2023, vested as to 2,768 shares on January 31, 2024, vested as to 2,769 shares on January 31, 2025, and will vest as to 2,769 shares on January 31, 2026, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,768 shares on January 31, 2023, vested as to 2,768 shares on January 31, 2024, vested as to 2,769 shares on January 31, 2025, and will vest as to 2,769 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,457 | $152.80 | $222,636.16 |
DisclosureSEC source: 0000914475-25-000029 · wk-form4_1738709691.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,373 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 31,188 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000029 · wk-form4_1738709691.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 27,770 | $0.00 Strike: $136.69 | $0.00 |
DisclosureSEC source: 0000914475-24-000226 · wk-form4_1734644819.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,770 Underlying: Common Stock · 27,770 shares Expires 2034-12-17 F3 · derivative.exercise_date: Represents an option of which 1/4 of the shares underlying the option becomes vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000226 · wk-form4_1734644819.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,487 Underlying: Common Stock · 5,487 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest 1/4 of the units on February 13, 2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028. F2 · derivative.expiration_date: The Restricted Stock Units will vest 1/4 of the units on February 13, 2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 1 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 8 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,265 Underlying: Common Stock · 1 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 971 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 7 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 971 shares Expires 2030-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 1,233 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 6 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,233 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 5,140 | $0.00 Strike: $77.81 | $0.00 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 5 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,140 shares Expires 2028-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1 | $79.02 | $79.02 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. F2 · balance_after: 29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 971 | $102.90 | $99,915.90 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,233 | $81.05 | $99,934.65 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 22:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,140 | $77.81 | $399,943.40 |
DisclosureSEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 23:52 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 42,467 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0000950170-24-071007 · ownership.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,467 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 23:52 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 11,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071007 · ownership.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,861 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,483 Underlying: Common Stock · 4,483 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 22,529 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,529 Underlying: Common Stock · 22,529 shares Expires 2034-02-13 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,114 | $132.96 | $148,121.78 |
DisclosureSEC source: 0000914475-24-000076 · wk-form4_1708037478.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,716 F1 · kind: Sale of 1,114 shares of common stock issued upon vesting of 2,113 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (999) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $134.21 | $131,521.98 |
DisclosureSEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,717 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F5 · balance_after: 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,121 | $142.24 | $159,446.11 |
DisclosureSEC source: 0000914475-24-000049 · wk-form4_1707438524.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,837 F1 · kind: Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.40 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,457 | $140.79 | $205,131.90 |
DisclosureSEC source: 0000914475-24-000031 · wk-form4_1706920138.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,832 F1 · kind: Sale of 1,457 shares of common stock issued upon vesting of 2,768 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,311) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.75 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $126.74 | $1,267,448.00 |
DisclosureSEC source: 0001209191-23-059774 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $128.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 18,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 6,947 | $81.05 Strike: $81.05 | $563,054.35 |
DisclosureSEC source: 0001209191-23-058683 · doc4.xml · derivative · entry 6 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,440 Underlying: Common Stock · 6,947 shares Expires 2029-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 6,978 | $81.05 Strike: $81.05 | $565,566.90 |
DisclosureSEC source: 0001209191-23-058683 · doc4.xml · derivative · entry 5 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,387 Underlying: Common Stock · 6,978 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,947 | $120.31 | $835,778.98 |
DisclosureSEC source: 0001209191-23-058683 · doc4.xml · nonDerivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 6,947 | $81.05 | $563,054.35 |
DisclosureSEC source: 0001209191-23-058683 · doc4.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,978 | $120.30 | $839,461.08 |
DisclosureSEC source: 0001209191-23-058683 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.